What is a Branch Retinal Vein Occlusion?
A branch retinal vein occlusion occurs when, because of hardening of the arteries, a branch retinal artery compresses a branch retinal vein causing blockage of the vein and decreased circulation in the distribution of that branch retinal vein. (see image) [note: the branch arteries are really arteriols and the branch veins are really veinules] There are several possible treatments for branch retinal vein occlusion including intravitreal injections, laser, and even surgery. Patients with BRVO lose vision for several reasons: poor circulation, hemorrhage and macular edema (swelling). There is no treatment, at the moment, to increase circulation or to remove hemorrhage. The macular edema, however, does respond well to intravitreal injections with Lucentis, Avastin, or steroids.Read more
Lucentis for Branch Retinal Vein Occlusion
Monthly Lucentis therapy is also helpful in improving vision in patients with branch retinal vein occlusion and macular edema. Without treatment about 30 percent of have visual improvement. With treatment about 60 percent of patients have improved vision. Long term follow-up show that at 4 years, about half of the patients with branch retinal vein occlusion require continued treatment to maintain the visual benefit.
Eylea for Branch Retinal Vein Occlusion
Eylea was approved for treatment of branch retinal vein occlusion in late 2014. It is administered as an intravitreal injection monthly initially and then the treatment interval can be extended.
Branch Retinal Vein Occlusion NEWS
Below are current articles from a Google News Feed on Branch Retinal Vein Occlusion
Ozurdex for retinal vein occlusion approved in China
The Chinese Food and Drug Administration has approved Ozurdex to treat adults with macular edema after branch retinal vein occlusion or central retinal vein occlusion, according to a press release from Allergan. Ozurdex (dexamethasone intravitreal ...
Allergan Gets China Approval For Ozurdex To Treat Retinal Vein Occlusion
(RTTNews) - Allergan plc (AGN) announced Monday that it has received an Imported Drugs License or IDL from the Chinese Food and Drug Administration or CFDA to market Ozurdex (dexamethasone intravitreal implant 0.7 mg) for the treatment of adult ...
Allergan Receives Approval for Ozurdex® (Dexamethasone Intravitreal Implant 0.7 mg) in China for the Treatment of ...
News of Note—Japanese robotics company Riverfield bags $10M; Abbott earns CE mark for next-gen stent
Japanese robotics player Riverfield scored 1.15 billion yen ($10.1 million) in new financing to fuel its mission to undercut Intuitive Surgical. Nikkei Asian Review article. > Abbott received a CE mark for its next-generation drug-eluting stent, the ...
Sustained Drug-Delivery Tech Shows Promise
"The future for sustained intravitreal drug delivery looks bright," said Glenn J. Jaffe, MD, of Duke University Eye Center in Durham, N.C., in an update during the Retina Subspecialty Day meeting. "Innovation occurring in this field shows promise to ...
IRIS Registry Finds New AMD, DME Population Data
Another study of randomized, controlled trials has found that previous reports of 10% retinal disease patients to receive anti-VEGF therapy experience potentially damaging pressure rise inside the eye may be a misconeption. Researchers reviewed 23,776 ...
World's Largest Clinical Specialty Database Yields Critical Insights to Advance Ophthalmic Patient Care
Largest clinical specialty database powers studies that yield key insights
Previous randomized, controlled trials have shown that close to 10 percent of patients who received anti-VEGF therapy for retinal diseases experience a pressure rise inside the eye that could be damaging. To learn more, researchers conducted a review ...
EpiCast Report: Macular Edema – Epidemiology Forecast to 2026
Macular edema (ME) is a condition characterized by the thickening and swelling (edema) of the macula, which is the area of the retina that is responsible for central vision. The occurrence of ME is highly frequent in diabetics and usually manifests ...
Widening use of dexamethasone implant for the treatment of macular edema
Dove Medical Press
Abstract: Sustained-release intravitreal 0.7 mg dexamethasone (DEX) implant is approved in Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious ...
Researchers confirm link between retinal vein occlusion, heart attack
“Similarly, the underlying mechanism of AMI involves a sclerotic artery (coronary artery), which causes thrombus formation and venous obstruction. We postulate that RVO and AMI may be associated because the changes in retinal vessels may somehow imply ...
Surgical eye robot performs precision-injection in patient with retinal vein occlusion
Researchers at University Hospitals Leuven and KU Leuven are studying retinal vein cannulation (RVC), a revolutionary treatment that addresses the cause of retinal vein occlusion by removing the blood clot in the retinal vein. RVC is a promising method ...
Bel Marra Health
Eye strokes (retinal artery occlusion): Symptoms, causes, and treatment
Bel Marra Health
Branch retinal artery occlusion (BRAO): Occurs suddenly and is typically painless. Vision loss can be appreciated as a loss of the peripheral vision, with some cases also losing central vision. Vein occlusion is usually caused by a clot or plaque that ...
Laser retains limited role for management of RVO-related ME
In the current era where pharmacologic therapy is the preferred treatment for macular edema secondary to retinal vein occlusion (RVO), there is still a role for laser, according to Francesco Bandello, MD. “Laser photocoagulation–especially subthreshold ...
MD Magazine (blog)
Ranibizumab Outperforms Aflibercept in Efficacy, Durability
MD Magazine (blog)
Additionally, the 5-year LUMINOUS study, which assessed the real-world efficacy of ranibizumab in more than 30000 patients with diabetic macular edema, branch retinal vein occlusion, central retinal vein occlusion and myopic choroidal ...
Should We WAVE Goodbye to Laser?
Secondary outcome measures included mean changes in central retinal thickness and safety analyses. The investigators found no additional benefits associated with TRP among primary or secondary outcome measures. There were no significant differences ...
European Society of Retina Specialists 17th EURETINA Congress
Predicting Anti-VEGF Response in Diabetic Macular Edema Response after 12 weeks of ranibizumab therapy can predict long-term outcomes in diabetic macular edema, a post hoc analysis suggests. Medscape Medical News, Sep 13, 2016. Prognostic Tests at 1 ...
Vital Art and Science Announces License Agreement with Genentech for Its mVT® Service
Business Wire (press release)
The mVT® Service is currently commercially available to retina specialists for patients with maculopathy, including dry and wet age-related macular degeneration, diabetic retinopathy, diabetic macular edema, macular pucker, macular hole, retinal vein ...
Regeneron (REGN) Stock on Fire: What's Behind the Surge?
The drug is also approved for macular edema following retinal vein occlusion, which includes macular edema post central retinal vein occlusion as well as macular edema following branch retinal vein occlusion. Meanwhile, Regeneron is working on ...
What is an Eye Stroke? Causes, Symptoms and Treatment
Consequently, the retina loses its blood supply and all the fluid and blood starts flooding the retina which results in swelling. At this point, medical attention is mandatory since there is a risk of loss of eyesight and permanent blindness. There are ...
European Retina Meeting Will Focus on Myopia Epidemic
BARCELONA — The prevention and treatment of the growing problem of myopia will be in the spotlight here at the 17th EURETINA Congress. "Myopia is becoming an epidemic all over the world, especially in Asian countries," said Anat Loewenstein, MD, from ...
Rescue alfibercept treatment proves successful for patients with BRVO
... provides significant visual benefits in patients treated with grid laser for macular edema associated with branch retinal vein occlusion (BRVO) at week 52 of the VIBRANT Study, said Jennifer Lim, MD. The VIBRANT Study was a 52-week, phase III trial ...
Despite Significantly Different Pricing, Similar Efficacy for Key Anti-VEGF Agents in Macular Edema
The goal of the multicenter clinical SCORE2 trial was to establish the safety and efficacy of bevacizumab compared with aflibercept in the treatment of macular edema secondary to central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO ...
Prognostic Tests at 1 Month Foretell Macular Edema Outcome
UPDATED September 14, 2016 // COPENHAGEN — For patients with macular edema secondary to branch retinal vein occlusion, some features seen on spectral-domain optical coherence tomography can predict long-term response to anti-VEGF therapy, a case ...
Retinal artery and vein thrombotic occlusion during pregnancy: markers for familial thrombophilia and adverse ...
Dove Medical Press
Results: Branch retinal artery occlusion (BRAO) occurred at 9 and 13 weeks gestation in two females, aged 32 and 35. Central retinal vein occlusion occurred immediately postpartum in a 40-year-old. One of the two females with BRAO subsequently ...
FDA OKs Ranibizumab for All Forms of Diabetic Retinopathy
Ranibizumab had been approved to treat diabetic retinopathy just in patients with DME on a monthly basis. The vascular endothelial growth factor (VEFG) inhibitor is indicated also for neovascular (wet) age-related macular degeneration, macular edema ...
Keeping An Eye On Clearside Biomedical
CLS-TA is an application of Clearside Biomedical's patented suprachoroidal space micro needle injection on triamcinolone acetonide, a steroid drug used for ocular conditions, including macular edema. Uveitis Phase III top-line trial results in Q1 2018 ...
FDA OKs Aflibercept (Eylea) for All Retinal Vein Occlusions
The US Food and Drug Administration (FDA) has expanded the indication of aflibercept (Eylea, Regeneron) injection to include all forms of macular edema after retinal vein occlusion (RVO), including branch RVO (BRVO), the manufacturer announced ...
NICE recommends Bayer drug for severe short-sightedness
NHS patients with severe short-sightedness will have access to a new therapy after NICE recommended Bayer's Eylea (aflibercept) for visual impairment due to myopic chorodial neovascularisation. The condition, known as myopic CNV for short, occurs in ...
... committed to ensuring that all eligible patients have access to Eylea in line with market authorisation so it is great news for patients with mCNV in England and Wales who will have access to this effective treatment as soon as it is adopted by ...
Notal Vision Welcomes Roni Amiel as Chief Information Officer
PR Newswire (press release)
Notal's next home-based telemonitoring application, the Notal Home OCT, may have the potential to expand the patient groups who benefit from ophthalmic telemedicine beyond wet AMD, to include diabetic macular edema, branch retinal vein occlusion, post ...
Prevalence of and risk factors for age-related macular degeneration in Nepal: the Bhaktapur Retina Study
Dove Medical Press
Aim: This study aimed to explore the prevalence of and risk factors for age-related macular degeneration (AMD) in an elderly population in Nepal. Subjects and methods: This is a population-based, cross-sectional study. A sample size of 2,100 was ...